Stockreport

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing [Yahoo! Finance]

Immunic, Inc.  (IMUX) 
PDF – Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc Analysis of Patients From Phase 1b Clinical Trial in Celiac Disease – – Dose-Dependent Reduc [Read more]